PNPLA3 rs738409: What Your Genotype Means
The rs738409 variant in the PNPLA3 gene is a well-studied genetic marker associated with variations in liver fat content. It is widely recognized as a significant genetic determinant for susceptibility to nonalcoholic fatty liver disease (NAFLD).
What each genotype means
Typical liver fat accumulation profile
You carry two copies of the C allele, corresponding to the ancestral isoleucine (I148) form of the PNPLA3 protein. In population studies, this genotype is associated with baseline rates of hepatic fat storage and a standard dietary response to carbohydrate and caloric intake. Because complex traits involve many factors, this genetic result alone does not indicate protection against metabolic liver changes.
Found in approximately 50% to 65% of individuals of European and African ancestries, though it is less frequent in East Asian and Hispanic populations.
Intermediate liver fat risk profile
You carry one copy of the G allele (often annotated as the 148M or I148M missense variant), which reduces triglyceride hydrolase efficiency in hepatocytes. Research indicates an intermediate statistical predisposition to hepatic fat accumulation and elevated liver enzymes, especially in the context of high carbohydrate or excess caloric intake. Lifestyle factors, overall metabolic health, and other genetic markers also significantly influence these biological outcomes.
Carried by approximately 30% to 45% of individuals across European, Asian, and Americas-ancestral cohorts.
Elevated liver fat risk profile
You have two copies of the G allele (148M homozygote), which is associated in genome-wide association studies with reduced lipid mobilization and higher susceptibility to hepatic steatosis. Cohort studies show individuals with this profile may exhibit a heightened tendency to store liver fat in response to high dietary sugars and refined carbohydrates. However, clinical studies also observe robust reductions in liver fat when adopting structured dietary and weight-management strategies.
Present in roughly 5% to 8% of individuals of European ancestry, about 10% to 20% in East Asian populations, and up to 25% or more in Hispanic/Latino populations.
Understanding the rs738409 Variant
The rs738409 variant is a single nucleotide polymorphism (SNP) located within the PNPLA3 gene. In scientific literature, this variant is frequently referred to as the I148M mutation, which describes a specific change in the protein sequence where the amino acid isoleucine is replaced by methionine at position 148. This change occurs because of a substitution of a cytosine (C) base for a guanine (G) base in the DNA sequence. Because this variant alters the structure of the resulting protein, it is classified as a nonsynonymous variant. Researchers have focused heavily on this SNP because it is one of the strongest genetic predictors of hepatic steatosis, or the accumulation of fat in the liver, across diverse human populations.
The Role of the PNPLA3 Gene
The PNPLA3 gene encodes a protein known as patatin-like phospholipase domain-containing protein 3, also called adiponutrin. This protein is primarily expressed in the liver and adipose tissue and plays a critical role in lipid metabolism. Specifically, the PNPLA3 protein is involved in the hydrolysis, or breakdown, of triglycerides stored in lipid droplets within cells. When the I148M variant is present, the normal hydrolytic function of the PNPLA3 protein is reduced. This impairment leads to the accumulation of triglycerides within liver cells, resulting in hepatic steatosis. While the exact mechanism is complex, current research suggests that the mutant protein may sequester essential cofactors or otherwise disrupt the normal mobilization of fats, thereby contributing to the development of fatty liver conditions.
Research Associations and Evidence
The association between the rs738409 G allele and increased liver fat content is supported by extensive genome-wide association studies. Research consistently shows that individuals carrying the G allele, particularly those who are homozygous (GG), have a significantly higher risk of developing NAFLD compared to those with the CC genotype. Interestingly, while this variant increases liver fat, some studies have observed that it may be associated with lower levels of central adiposity and improved metabolic profiles in other areas, such as reduced insulin resistance. It is important to note that while the statistical association with liver fat is strong, the evidence regarding its impact on broader cardiovascular outcomes remains mixed. As with all genetic markers, this variant is only one piece of a complex puzzle involving diet, lifestyle, and other genetic factors.
What This Information Means for You
Knowing your genotype for rs738409 provides insight into your genetic predisposition toward liver fat accumulation, but it is not a medical diagnosis. Genetic testing for this variant cannot predict with certainty whether you will develop liver disease, as environmental factors like diet, physical activity, and alcohol consumption play major roles in liver health. If you are concerned about your liver health or have questions about your genetic results, you should consult with a healthcare professional or a hepatologist. They can provide context based on your personal medical history, blood tests, and imaging studies. Never use genetic information to make changes to your medical care or lifestyle without professional guidance, and remember that genetic risk is not destiny; many individuals with higher-risk genotypes maintain healthy liver function through lifestyle management.
How common is this variant?
The G risk allele is most common in Hispanic populations, with frequencies often reported around 0.49, while it is less common in African populations, where frequencies are approximately 0.15.
Frequently asked questions
Is the PNPLA3 rs738409 variant a diagnosis for fatty liver disease?
No, this variant is a genetic marker associated with a higher statistical risk of developing fatty liver. It is not a diagnostic test for NAFLD, which requires clinical evaluation by a doctor.
Can I change my risk if I have the GG genotype?
Yes, lifestyle factors such as maintaining a healthy weight, regular physical activity, and a balanced diet are critical in managing liver health regardless of your genetic background. Consult your physician for personalized health strategies.
Why is this variant more common in some ancestries?
Genetic variants often vary in frequency across populations due to historical migration, natural selection, and genetic drift. The prevalence of the G allele is notably higher in Hispanic populations compared to others.
Does this variant affect how I should take medication?
There is no standard clinical guideline for medication dosing based solely on this variant. Always discuss any concerns about your medications or potential side effects with your clinician or pharmacist.
Sources & further reading
Educational information only, last refreshed 10/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs738406?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in PNPLA3
Intronic regulatory variant in linkage disequilibrium with I148M associated with hepatic fat fraction and ALT levels.
This variant is in high linkage disequilibrium with the I148M (rs738409) variant, which is a major genetic determinant of hepatic fat content and susceptibility to NAFLD.
The PNPLA3 S453I variant is a rare variant associated with hepatic lipid metabolism; note that the common risk variant for NAFLD is rs738409.
An intronic variation in linkage disequilibrium with the major PNPLA3 non-alcoholic fatty liver disease (NAFLD) locus that contributes to individual liver fat accumulation and fibrosis predisposition.
The PNPLA3 I148M variant is a major genetic risk factor for non-alcoholic fatty liver disease (NAFLD) and progression to cirrhosis.
This variant is associated with increased risk of non-alcoholic fatty liver disease and liver fat accumulation.